Case 1 – Treatment of uterine sarcoma with 3-hour trabectedin intravenous infusion

 

Authors

  • E. Bertone Gynaecologic Department, Medical Oncology Unit, Ospedale S. Anna, Torino, Italy.
  • G. Richiardi Gynaecologic Department, Medical Oncology Unit, Ospedale S. Anna, Torino, Italy.
  • D. Katsaros Gynaecologic Department, Medical Oncology Unit, Ospedale S. Anna, Torino, Italy.
  • G. Gregori Gynaecologic Department, Medical Oncology Unit, Ospedale S. Anna, Torino, Italy.
  • S. Danese Gynaecologic Department, Medical Oncology Unit, Ospedale S. Anna, Torino, Italy.

Abstract

We report a case of advanced uterine leiomyosarcoma treated with trabectedin first-line, in a patient unfit for standard chemotherapy treatment, with off-label schedule of 3 hours infusion. The patient had a progressive disease by RECIST after 3 cycles of trabectedin, with improvement of Eastern Cooperative Oncology Group (ECOG) perfomance status and early signs of tissue response; after 6 cycles we got a partial response by RECIST that has been confirmed after 13 cycles of trabectedin with no relevant toxicity. We showed that trabectedin administered in first-line and with an off-label schedule could be effective in advanced uterine leiomyosarcoma; the response could appear later and RECIST criteria for the evaluation of response may be not effective with this drug.